Adirondack Trust Company’s Biogen BIIB Stock Holding History

Adirondack Trust Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.3K	Hold	80	–	–	0.01%	366
2026 Q1	$14.7K	Hold	80	–	–	﹤0.01%	359
2025 Q4	$14.1K	Hold	80	–	–	﹤0.01%	358
2025 Q3	$11.2K	Hold	80	–	–	﹤0.01%	388
2025 Q2	$10K	Hold	80	–	–	﹤0.01%	365
2025 Q1	$10.9K	Hold	80	–	–	﹤0.01%	341
2024 Q4	$12.2K	Hold	80	–	–	﹤0.01%	338
2024 Q3	$15.5K	Hold	80	–	–	0.01%	328
2024 Q2	$18.5K	Sell	80 -1	-1%	-$217	0.01%	309
2024 Q1	$17.5K	Buy	81 +1	+1%	+$234	0.01%	313
2023 Q4	$17.4K	Hold	80	–	–	0.01%	313
2023 Q3	$20.6K	Hold	80	–	–	0.01%	283
2023 Q2	$21.6K	Hold	80	–	–	0.01%	265
2023 Q1	$22.2K	Sell	80 -1	-1%	-$277	0.01%	259
2022 Q4	$22.4K	Hold	81	–	–	0.01%	254
2022 Q3	$22K	Hold	81	–	–	0.01%	248
2022 Q2	$17K	Buy	81 +68	+523%	+$13.9K	0.01%	259
2022 Q1	$3K	Hold	13	–	–	﹤0.01%	392
2021 Q4	$3K	Hold	13	–	–	﹤0.01%	385
2021 Q3	$3K	Hold	13	–	–	﹤0.01%	370
2021 Q2	$5K	Hold	13	–	–	﹤0.01%	334
2021 Q1	$4K	Hold	13	–	–	﹤0.01%	344
2020 Q4	$4K	Buy	+13	New	+$3.35K	﹤0.01%	321
2020 Q3	–	Sell	-8	Closed	-$2K	–	335
2020 Q2	$2K	Hold	8	–	–	﹤0.01%	321
2020 Q1	$3K	Hold	8	–	–	﹤0.01%	297
2019 Q4	$2K	Sell	8 -20	-71%	-$5.55K	﹤0.01%	326
2019 Q3	$7K	Sell	28 -22	-44%	-$5.12K	﹤0.01%	265
2019 Q2	$12K	Hold	50	–	–	0.01%	248
2019 Q1	$11K	Sell	50 -10	-17%	-$3.15K	0.01%	240
2018 Q4	$18K	Hold	60	–	–	0.01%	205
2018 Q3	$21K	Sell	60 -5	-8%	-$1.72K	0.01%	203
2018 Q2	$19K	Hold	65	–	–	0.01%	202
2018 Q1	$18K	Buy	65 +2	+3%	+$621	0.01%	207
2017 Q4	$20K	Hold	63	–	–	0.01%	200
2017 Q3	$20K	Hold	63	–	–	0.02%	199
2017 Q2	$17K	Sell	63 -35	-36%	-$9.26K	0.01%	207
2017 Q1	$27K	Sell	98 -65	-40%	-$18.4K	0.02%	193
2016 Q4	$46K	Sell	163 -5	-3%	-$1.48K	0.03%	164
2016 Q3	$53K	Buy	168 +60	+56%	+$17.8K	0.04%	161
2016 Q2	$26K	Buy	108 +8	+8%	+$2.11K	0.02%	214
2016 Q1	$26K	Hold	100	–	–	0.02%	191
2015 Q4	$27K	Hold	100	–	–	0.02%	186
2015 Q3	$29K	Buy	100 +5	+5%	+$1.65K	0.02%	178
2015 Q2	$38K	Buy	95 +20	+27%	+$8.03K	0.03%	172
2015 Q1	$32K	Sell	75 -10	-12%	-$3.94K	0.02%	183
2014 Q4	$29K	Buy	85 +35	+70%	+$11.3K	0.02%	189
2014 Q3	$17K	Buy	50 +30	+150%	+$9.89K	0.01%	227
2014 Q2	$6K	Buy	+20	New	+$6.02K	﹤0.01%	285

Other funds holding BIIB

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

CIM

Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Adirondack Trust Company's BIIB Position: Q2 2026 in Review

Adirondack Trust Company held its Biogen (BIIB) position steady in Q2 2026 at 80 shares worth $17.3K. The position accounts for 0.01% of the portfolio, ranked #366.

Adirondack Trust Company first reported a position in BIIB in Q2 2014 and has held it in 48 quarters since. The position peaked at $53K in Q3 2016. 149 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Adirondack Trust Company held 80 shares of Biogen worth $17.3K as of Q2 2026.
Adirondack Trust Company left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.01% of Adirondack Trust Company's portfolio in Q2 2026, its #366 holding.
Adirondack Trust Company first reported a position in Biogen in Q2 2014 and has held it in 48 quarters since.
Adirondack Trust Company's Biogen position peaked at $53K in Q3 2016.
149 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.